RxDoctor Payments Data

Victor Sanchez, MD

Cardiovascular Disease · Manati, PRNPI 1558301788

Payments from drug & device makers

$5,087in general payments, 2019–2025

Across 45 payments — averaging $113.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Abbott$310
  • Boston Scientific$284
  • AstraZeneca$147
  • Impulse Dynamics (USA) Inc.$122
  • E.r. Squibb & Sons, L.L.C.$107
  • plus $130 from 3 others

What the payments were for

  • Travel & lodging$1,57131%
  • Food & beverage$3,51669%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,087 in reported general payments places this provider in the 65th percentile of 267 cardiovascular disease providers in Puerto Rico.

See all cardiovascular disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$6,288
Medicare patients
17
Services billed
90

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban230$143,603
FarxigaDapagliflozin Propanediol132$83,693
EntrestoSacubitril/Valsartan68$49,719
XareltoRivaroxaban24$17,051
Candesartan Cilexetil218$15,748
Repatha SyringeEvolocumab19$11,909
Metoprolol Succinate977$11,263
Chlorthalidone893$11,101
Atorvastatin Calcium1,151$9,182
JardianceEmpagliflozin13$8,591
SynthroidLevothyroxine Sodium132$7,892
TradjentaLinagliptin13$6,857
Ezetimibe316$4,577
Candesartan-HydrochlorothiazidCandesartan/Hydrochlorothiazid35$3,462
Cilostazol147$3,427

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$147$83,693132 claims
Johnson & JohnsonXarelto$28$17,05124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 267 cardiovascular disease providers in Puerto Rico.

Other cardiovascular disease in Manati

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →